Senior Director, Project Management

Contact Information
Contact Name: 
Elusys Therapeutics, Inc.
Organization Name: 
Elusys Therapeutics, Inc.
Position Location: 
Pine Brook, NJ
Contact Email: 

Manage and direct cross functional team of research, development, manufacturing, clinical and regulatory personnel and other key consultants and subcontractors for the timely and efficient development and commercialization of the company’s therapeutic programs. Responsible for overseeing projects, managing resources, timelines and budgets and identifying program problems and challenges and developing plans to resolve problems. Overall responsibility for the development of team generated project plans. Leads the definition of the development process and timeline.

Analyze current project operations and make recommendations for improvement. Facilitate information flow among team members, senior management and corporate clients. Organize interdepartmental activities ensuring completion of projects on schedule and within budget constraints. Regularly interact with senior management. Requires the ability to change the thinking of or gain acceptance of others in sensitive situations. Work on special projects with senior management as requested.

Position Requirements:
Microsoft Project, server based, experience a must. Drug development project management experience a must. Experience should be directly related to participation in late stage drug development and the submission of either an NDA or BLA. Requires a masters of PhD in a scientific discipline or PMP certification, business/marketing experience is preferred. Must have previous experience managing pharmaceutical projects.

Years of Experience: 5 – 10 years
Degree: Masters or PhD

Additional Job or Internship Information
Position Type: 
Full time job
Organization Profile: 
Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. Anthim has consistently demonstrated significant efficacy in multiple non-clinical animal studies and has been successfully evaluated in two clinical saftey trials.